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Abstract
Pediatric rhabdomyosarcoma (RMS) is a morphologically and genetically heterogeneous malignancy commonly classified
into three histologic subtypes, namely, alveolar, embryonal, and anaplastic. An issue that continues to challenge effective
RMS patient prognosis is the dearth of molecular markers predictive of disease stage irrespective of tumor subtype. Our
study involving a panel of 70 RMS tumors has identified specific alternative splice variants of the oncogenesMurine Double
Minute 2 (MDM2) and MDM4 as potential biomarkers for RMS. Our results have demonstrated the strong association of
genotoxic-stress inducible splice forms MDM2-ALT1 (91.6% Intergroup Rhabdomyosarcoma Study Group stage 4 tumors)
and MDM4-ALT2 (90.9% MDM4-ALT2–positive T2 stage tumors) with high-risk metastatic RMS. Moreover, MDM2-ALT1–
positivemetastatic tumors belonged to both the alveolar (50%) and embryonal (41.6%) subtypes, making this the first known
molecular marker for high-grade metastatic disease across themost common RMS subtypes. Furthermore, our results show
thatMDM2-ALT1 expression can function by directly contribute tometastatic behavior and promote the invasion of RMScells
through a matrigel-coated membrane. Additionally, expression of both MDM2-ALT1 and MDM4-ALT2 increased anchorage-
independent cell-growth in soft agar assays. Intriguingly, we observed a unique coordination in the splicing of MDM2-ALT1
and MDM4-ALT2 in approximately 24% of tumor samples in a manner similar to genotoxic stress response in cell lines. To
further explore splicing network alterations with possible relevance to RMS disease, we used an exon microarray approach
to examine stress-inducible splicing in an RMS cell line (Rh30) and observed striking parallels between stress-responsive
alternative splicing and constitutive splicing in RMS tumors.
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Introduction
Alternative splicing of pre-mRNA is the major contributor to pro-
teome diversity and has an immense impact on the physiology of
the cell both under normal and disease states. It is therefore no sur-
prise that altered or aberrant splicing of several oncogenic and tumor
suppressor genes and/or alterations in splicing regulatory pathways
can play crucial roles in carcinogenesis. Alternative splicing of onco-
genes murine double minute 2 (MDM2) and MDM4, chief negative
regulators of the tumor suppressor p53, is another such phenomenon
that has been observed frequently in several tumor types. At least
10 bona fide alternative splice variants of MDM2 have been reported
in a variety of tumors including soft tissue sarcomas (STSs), ovarian
and bladder cancers, glioblastomas, lymphomas, and breast cancer
[1–10] with the most common splice variant being MDM2-ALT1,
a form that is also induced in a variety of cell lines under genotoxic
stress conditions [11,12]. MDM4 alternative splicing has been
reported in lung carcinomas, thyroid tumors, and STS tumors [13–
15] with MDM4-S and MDM4-211 being two common splice
variants characterized in these studies. Nonetheless, the consequences
and the relation of these altered splicing events to disease outcome in
these tumors remain poorly understood.
RMSs are a relatively rare type of STS that arise primarily in chil-
dren and adolescents and are currently histologically categorized into
three main subtypes according to the International Classification of
Rhabdomyosarcoma, namely, alveolar RMS (ARMS), embryonal
RMS (ERMS), and anaplastic RMS. Although a variety of onco-
genic events such as PAX3/7-FORKHEAD translocation and MYCN
amplification as well as alterations in signaling pathways such as insulin
receptor, nuclear factor kappa-light-chain-enhancer of activated B cells
(NFKB), RAS, Sonic Hedgehog, and integrin-linked kinase have been
implicated in the etiology of this disease [16–23], there remains the
need for reliable molecular prognostic biomarkers for RMS. In fact,
currently prognosis and treatment is based on age of onset, extent of
disease following definitive surgery, and PAX3/7-FORKHEAD trans-
location status (for ARMS).
A phenomenon that has consistently been observed in RMS tumors
is the alternative splicing of MDM2 and MDM4. For instance, Bartel
et al. reported the occurrence of 10 different alternative MDM2 tran-
scripts including common splice variants MDM2-ALT1 and MDM2-
ALT2 in 75% (6 of 8) of RMS cell lines and 82% (9 of 11) of RMS
patient tumor samples tested [7]. However, the exact significance
of these splicing events in RMS prognosis is unknown. A previous
study that endeavored to do so on a generalized STS tumor panel
was hampered by the small representation of RMS tumors in the
cohort (four RMS samples) and the fact that not all alternative
MDM2 transcripts considered in this analysis may represent bona
fide splice variants [1]. Nevertheless, the above study and others on
ovarian and bladder cancers did reveal an association of advanced-stage
tumors with the alternative MDM2 transcripts [1,2]. In the case of
MDM4, previous studies have shown that at least one splice variant
MDM4-S is associated with poor prognosis in a panel of 66 STS tumors
that included 14 RMS samples [15,24], although the analysis did not
focus on assessing this association in the individual STS tumor sub-
types. Nevertheless, these studies indicate the prognostic potential of
MDM2 and MDM4 alternative splicing.
In this study, we have endeavored to systematically characterize the
alternative splicing of MDM2 and MDM4 in a panel of 70 RMS
tumors that were segregated into the following three subtypes: ARMS,
ERMS, and anaplastic RMS. We have shown an overt RMS subtype
bias for the occurrence of the splice formsMDM2-ALT1 andMDM4-
ALT2, which previous studies have shown to be induced on genotoxic
stress treatment in multiple cell lines [11]. Importantly, we have
observed a statistically significant association of these forms with
advanced-stage and metastatic RMS disease that is not subtype spe-
cific, thereby highlighting their potential to serve as molecular prog-
nostic markers for RMS irrespective of tumor subtype. Additionally,
we show here that MDM2-ALT1 can increase the invasive behavior
of RMS cell lines, indicating that this splice variant can influence
RMS tumor metastatic behavior.
Further, we report a unique coordination in the alternative splicing
of MDM2 and MDM4 in these RMS tumors similar to that observed
during genotoxic stress response in cell lines [11]. This observation led
us to investigate whether or not similarities exist between the splicing
landscapes of RMS tumors and genotoxic stress response. Indeed,
a transcriptome-wide analysis of stress-induced splicing changes in
an RMS cell line revealed at least a few parallels between splicing pat-
terns in tumors and genotoxic stress response. Essentially, our study
has identified stress-responsive alternative splicing pathways as an
important link in RMS etiology that can be potentially exploited for
therapeutic purposes.
Materials and Methods
RNA Extraction from RMS Tissues and Reverse
Transcription–Polymerase Chain Reaction Amplification
of MDM2, MDM4, and GAPDH Transcripts
Human tissue samples were obtained from the Cooperative Human
Tissue Network, Pediatric Division at Columbus Nationwide Chil-
dren’s Hospital after Institutional Review Board approval. All spec-
imens were snap-frozen and stored at −80°C. The tissue was ground
using a mortar and pestle in liquid nitrogen. RNA was extracted from
tissue samples (25-40 mg) using RNeasy Mini Protocol (Qiagen,
Valencia, CA). Typically 4 μg of RNA was used for reverse transcrip-
tion (RT) in 20-μl reactions. Human MDM2 and MDM4 RNA from
RMS cell lines and tumor and normal tissue samples were amplified
using a nested set of primers as reported previously [11,25] or using
the same internal primers in combination with the following external pri-
mers: HDM2 Ex Sn 2 (GAAGGAAACTGGGGAGTCT) and HDM2
Ex Asn 2 (GAGTTGGTGTAAAGGATG). For the detection of glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) transcripts, cDNA was
amplified using a set of human GAPDH-specific primers: 5′-GATGC-
TGGCGCTGAGTACG-3′ (forward) and 5′-GCTAAGCAGTTGG-
TGGTGC-3′ (reverse). Additionally, all alternatively spliced variants
of MDM2 and MDM4 amplification were confirmed by sequencing.
RT and Polymerase Chain Reactions
Typical RT reactions were carried out using 4 μg of RNA
unless otherwise mentioned. Transcriptor RT enzyme (Catalog
No. 03531287001) from Roche Diagnostics (Indianapolis, IN) was
used for the cDNA synthesis reactions according to the manufac-
turer’s instructions. Polymerase chain reactions (PCRs) were per-
formed using Taq Polymerase from either Sigma-Aldrich (Catalog
No. D6677) or Roche (St Louis, MO; Catalog No. D6677) under
standard PCR conditions.
Statistical Analysis of Patient Outcome Data
GraphPad Prism 5.0b was used to perform statistical analyses for
RMS subtype specificity of MDM2-ALT1 and MDM4-ALT2 splicing
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in the 70 patient tumor samples. The tumor patient outcome data
were analyzed for association with alternative splicing of MDM2 and
MDM4 by the Children’s Oncology Group (COG). The MDM
splicing variants were checked for association with the demographic
characteristics of the patients within the RMS analytic population
by the exact conditional test of proportions. Age at enrollment was
checked in this manner as a categorical variable (<1, 1-9, ≥10 years)
and also as a continuous variable using the t test or a one-way analysis
of variance (ANOVA), as appropriate. When an ANOVA was done,
the patient groups were assessed for significant differences using Tukey
95% confidence intervals (CIs) on the differences; only the statistically
significant CIs (if any) were displayed. The outcomes in terms of
event-free survival (EFS) and survival were compared among RMS
patient groups defined by the presence or absence of each MDM splic-
ing variant. EFS was taken to be the time from enrollment until dis-
ease progression, diagnosis of a second malignant neoplasm, death, or
last patient contact, whichever occurred first. The EFS and survival of
patient groups were each estimated by the Kaplan-Meier method. The
relative risks for EFS event and death were compared across the groups
using the log-rank test stratified by RMS risk classification (low, inter-
mediate, or high), as appropriate. Additionally, proportional hazards
regression model was used on each of the MDM splicing variants.
The analyses were done in SAS 9.2 using PROC LIFETEST and
PROC FREQ.
Western Blot Analysis and Antibodies
The normal and tumor tissue samples were ground using a mortar
and pestle in liquid nitrogen and then lysed in NP-40 buffer. Equal
amounts of protein (20 μg) were loaded in 1× sodium dodecyl sul-
fate (SDS) sample buffer onto a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis gel (SDS-PAGE) and blotted onto a polyvinylidene
difluoride (PVDF) membrane and analyzed for expression of p53
(DO-1, sc-126, 0.2 μg/ml; Santa Cruz Biotechnology, Dallas, TX),
p21 (F-5, sc-6246, 0.2 μg/ml; Santa Cruz Biotechnology), Bax (B-9,
sc-7480, 0.2 μg/ml; Santa Cruz Biotechnology), and β-actin (AC-15,
A5441; Sigma). For detection of LacZ, myc-tag antibody SC40 clone
9E10 (Santa Cruz Biotechnology) was used (0.2 μg/ml). To detect ex-
pression of MDM2-ALT1, the MDM2 N-20 antibody (sc-813; Santa
Cruz Biotechnology) was used (0.2 μg/ml) and MDM4-ALT2 expres-
sion was verified with MDMX MaxPab (B01P; Abnova, Jhongli City,
Taiwan). Protein sizes were determined using the Precision Plus
Protein Dual Color Standards marker (Invitrogen, Grand Island,
NY; Catalog No. 161-0374).
Cell Culture, Growth, and Transfection Conditions
ERMS cell lines RD2, Rh36, and SMS-CTR and ARMS cell
lines Rh3, Rh18, Rh28, Rh30, and CW9019 were maintained in
RPMI 1640 media supplemented with 10% FBS (Hyclone, Logan,
UT), L-glutamine (Cellgro, 25-005 CI), and penicillin/streptomycin
(Cellgro, 30-001 CI). Likewise, MCF7 breast cancer cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% FBS, L-glutamine, and penicillin/streptomycin.
For damage treatment, cells were plated at 50% to 60% confluency,
grown at 37°C overnight, treated with 0, 25, or 50 μM cisplatin,
and harvested for total RNA (RNeasy Mini Protocol; Qiagen) after
24 hours; 1 mg/ml stock of cisplatin (manufactured for Teva Paren-
teral Medicine Inc, Irvine, CA, and obtained from the Nationwide
Children’s Hospital pharmacy) in sodium chloride solution (pH 3.2-
4.4) was used for cisplatin treatment of cells. For transient transfec-
tion of Rh30 and C2C12 cells, Amaxa Cell Line Nucleofector V Kit
was used according to the manufacturer’s instructions with Nucleo-
fector Program B-032. Cells were allowed to recover for 24 hours
before further experiments were performed. The cells were then de-
tached from the plates using Accutase (Innovative Cell Technologies,
San Diego, CA; AT-104). Single cell suspensions were made, and
cells were counted for use in the matrigel invasion assay and the
focus-forming assay or for protein lysates for Western blot analysis
of protein expression.
Plasmids and Protein Expression Constructs
LacZ, MDM2-ALT1, and MDM4-ALT2 cDNA were cloned into
the BglII-XhoI sites of the Cre-inducible pCALL2 vector [26] whose
β-galactosidase and neomycin resistance cassettes were previously
excised by Cre recombinase to facilitate constitutive expression of the
corresponding downstream cDNA. These constructs were used for
transient overexpression of these proteins in Rh30 and C2C12 cells.
Matrigel Invasion Assay
Rh30 cells were electroporated with LacZ, MDM2-ALT1, or
MDM4-ALT2 expression plasmids. Fifty thousand cells resuspended
in RPMI 1640 with 2% FBS were seeded into BD BioCoat Matrigel
Invasion Chambers (354480) with 8-μm pores according to the
manufacturer’s instructions and incubated in wells containing RPMI
1640 with 15% FBS for 20 hours. The inserts were then removed
from the invasion chambers, and cells from the inner surface of the
membrane were scraped off. Cells that were able to migrate through
the membrane pores to the outer surface were then fixed, stained in
toluidine blue, and mounted on slides. The slides were then imaged
using the Olympus BX51 microscope (×10 magnification) equipped
with a CX9000 camera. The cells that were present on the outer
surface of the membrane (invading cells) were counted using the
Stereo Investigator (9.10.5) and Neurolucida (4.60.1) software (MBF
Biosciences, Williston, VT). Data were analyzed as the number of in-
vading cells for each group (LacZ, MDM2-ALT1, and MDM4-ALT2
expression) from three independent experiments. Statistical analysis
(unpaired Student’s t test, 95% CI) was performed using the GraphPad
Prism software version 6.0a.
96-Well Soft Agar Assays
The protocol for assessing the growth and foci-forming ability of
transiently transfected cells in soft agar was adapted from Ke et al.
[27]. Rh30 or C2C12 cells were electroporated with LacZ, MDM2-
ALT1, or MDM4-ALT2 expression plasmids; 4000 cells/well for
Rh30 and 1000 cells/well for C2C12 cells were mixed with 0.35%
LMP agarose (Invitrogen; Catalog No. 15517-022) in DMEM or
RPMI 1640 with 10% FBS and plated onto 0.7% base agar (LMP
agarose in DMEM or RPMI 1640 with 10% FBS) in individual wells
of a 96-well plate (Corning Costar 3595). The agar was allowed to
solidify, and a feeder layer of media was added on top of the solid
cell layer. Resazurin dye (final concentration of 44 mM) was added
to the individual wells on day 0 (8-12 hours post seeding in soft
agar), day 2, day 4, or day 7 of growth and incubated at 37°C for
4 hours after which fluorescence measurements (530-nm excitation
and 590-nm emission) of resazurin reduction by cells was measured
using a plate reader (Molecular Devices spectramax M2A). All fluo-
rescence readings were corrected for background using a “blank”
well containing only the soft agar layers without the cells. Two-way
ANOVA with Holm-Sidak multiple comparisons test was performed
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between the LacZ, MDM2-ALT1, and MDM4-ALT2 expression
groups across the different time points using GraphPad Prism version
6.0a. All significance values were determined at 95% CI.
Ribosomal RNA Profile Analysis
RH3 cells were subjected to 50 J/m2 UV 12 hours before har-
vest. Polysome preparations were performed as previously described
[28]. RNA was precipitated with ethanol from each fraction and
harvested using RNeasy Mini Protocol (Qiagen). Nested RT-PCR
with MDM2- and MDM4-specific primers was performed [11]. Addi-
tionally, total RNA from each fraction of the sucrose gradient was
separated using denaturing RNA gel electrophoresis and visualized
by ethidium bromide staining to confirm the distribution of poly-
ribosomes in higher fractions of the gradient.
Exon Microarray and Target Validation
Rh30 RMS cells were treated with 75 μM cisplatin for 12 hours,
and RNA was harvested both from treated and normal cells accord-
ing to current Affymetrix protocols. The Human GeneChip Human
Exon 1.0 ST Array was then used to analyze the RNA changes in
RNA splicing and expression levels. Three biologic replicates were per-
formed for each condition (normal and cisplatin treated). Quality con-
trol (QC) plots were generated to highlight outlying arrays or potential
issues with samples. All six hybridizations exceeded the expected quality
control metrics. None of the samples had an outlying distribution, and
after normalization, the distribution of probe intensities was the same
for all the arrays. Validation of the microarray targets was performed in
Rh30 and MCF7 cells treated with 75 μM cisplatin or 50 J/m2 UV for
24 hours. The primers used for target validation are listed in Table W2,
A and B. For validation of alternative splicing of the targets, PCRs were
typically carried out for 35 cycles at indicated annealing temperatures
(Table W2A) and extension of 72°C. For validation of gene expres-
sion, semiquantitative PCRs were typically carried out at 25 cycles with
indicated annealing temperatures (Table W2B) and extension of 72°C.
Exon Microarray Data Analysis
Affymetrix exon array data were analyzed using Partek Genomics
Suite. Data were imported to Partek as Affymetrix.CEL files. Differ-
entially expressed genes between normal and cisplatin-treated samples
were determined using Partek’s ANOVA algorithm, and alternative
splicing was analyzed with the alternative splice detection algorithm.
Genes that showed P < .05 with false discovery rate (FDR) correction
were deemed significantly differentially expressed and differentially
spliced. Differentially expressed genes included in analyses also demon-
strated greater than two-fold increase in expression. For functional
annotation analysis of the genes showing alternative splicing under cis-
platin treatment, DAVID Bioinformatics Resources v6.7 [29] was used.
RMS Tumor Validation of Exon Array Targets
One microgram of the RNA isolated from the tumor samples A4217,
A1063, and E2035 was used for RT. For use as controls, three separate
preparations of normal skeletal muscle RNA were obtained from Life
Technologies (Grand Island, NY; Lot 1201011 and Lot 1207012) and
Clontech (Mountain View, CA; Lot 1202764A), and 1 μg of RNA
from each sample was used for RT. The primers used for the various
PCRs and the annealing temperatures are listed in Table W2A.
Results
Alternatively Spliced MDM2 Transcripts in Pediatric RMS
Tumor Samples Reveal Subtype Specificity
We sought to understand if a specific pattern underlies the con-
stitutive appearance of MDM2 splice variants in RMS tumors. To
this end, we screened a total of 70 human RMS patient tumor samples
classified into the following three RMS categories according to the
revised International Classification of Rhabdomyosarcoma: ARMS
(n = 27), ERMS (n = 23), and anaplastic RMS (n = 20). Besides the
morphologic and pathologic examination, we characterized the
alveolar samples by their PAX3-FKHR t(2;13)(q35;q14) and PAX7-
FKHR t(1;13)(p36;q14) translocation status using a PCR-based assay
as previously described [30]. These aberrations, resulting in a fusion
of two transcription factors PAX3 and FKHR (FORKHEAD) or
PAX7 and FKHR, respectively, are a common feature of most ARMS
tumors. A total of 17 of 27 ARMS tumors (approximately 63%) were
positive for the translocations with 8 of these samples showing the
PAX3-FKHR t(1;13)(q35;q14) fusion and 9 samples showing the
PAX7-FKHR t(2;13)(p36;q14) translocation. One normal tissue
(N1008), obtained from a patient with RMS, was subjected to
RT-PCR as negative control for the characteristic translocation
(Table W1). In addition, one anaplastic RMS tumor (Ana2013) was
positive for the PAX3-FKHR translocation.
We harvested RNA from the RMS tumors and assayed them
for the presence of alternative splice forms of MDM2. We found
that 23 of 27 (85%) ARMS tumors and 16 of 23 (70%) ERMS
tumors expressed the genotoxic stress–inducible form MDM2-
ALT1 (Figure 1A and Table W1) with no statistically significant
difference (P > .2, χ2 test) between these two subtypes for the ex-
pression of MDM2-ALT1 (Figure 1B). In addition, there was no
statistically significant correlation between the expression of MDM2-
ALT1 and the characteristic translocations found in the alveolar sub-
type, although the number of samples studied was relatively small
(n = 27). Strikingly, only 2 of 20 anaplastic RMS samples (10%;
Figure 1A and Table W1) expressed MDM2-ALT1. This difference
was statistically significant when compared to ARMS and ERMS
tissues as indicated by χ2 test P value (P < .001; Figure 1B). We exam-
ined the normal human skeletal muscle tissue corresponding with five
of these RMS patients, and we did not observe MDM2-ALT1 in any
of the samples (Figure 1A). This indicates tumor specificity for the
constitutive expression of MDM2-ALT1. Additionally, we did not
observe any change in the GAPDH levels, used as control, in any of
the RMS tumors or normal tissue from patients with RMS (Figure 1A).
To conclude, we observed a strong correlation of the presence of
MDM2-ALT1 with ARMS and ERMS but not with anaplastic
RMS, indicating a subtype difference previously overlooked.
Alternatively Spliced MDM4 Transcripts in Pediatric
RMS Tumor Samples
In response to genotoxic stress, MDM2-ALT1 is induced in coordi-
nation with alternative splice variants of close family member MDM4
[11]. Moreover, constitutively altered splicing of MDM4 has been
reported in non–small cell lung cancer, papillary thyroid carcinoma,
osteosarcoma, and several types of STSs [13–15,24]. Therefore, we
assayed the RNA from the RMS tumor samples for the presence of
MDM4 alternative transcripts. Four of the ARMS tumor samples that
expressed neither full-length MDM4 nor its splice variants (A0295,
A1067, A201, and A1049) were not included in the statistical analysis
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for MDM4 alternative splicing. Of the remaining ARMS samples,
10 of 23 (43%) expressed MDM4-ALT2 (Figure 1A and Table W1),
a stress-inducible splice variant ofMDM4 [11]. Of the ERMS samples,
9 of 23 (39%) expressed MDM4-ALT2 (Figure 1A and Table W1).
Interestingly, none of the anaplastic RMS samples expressed MDM4-
ALT2 (Figure 1A and Table W1), although 35% (7 of 20) of them
expressed other MDM4 splice variants including another stress-
inducible splice variant MDM4-ALT1 [11]. The presence of MDM4-
ALT2 shows a strong correlation (P < .001, χ2 test) with ARMS and
ERMS but not with anaplastic RMS (Figure 1C ). In addition, there
was no statistical difference (P > .2, χ2 test) between the alveolar and
the embryonal subtypes for expression of MDM4-ALT2 (Figure 1C).
Similar to MDM2-ALT1, the ARMS samples showed no statistically
significant correlation (P > .2, χ2 test) between their translocation
status and the presence of MDM4-ALT2 (n = 23). When we exam-
ined the five normal human tissues from patients with RMS, we did
not observe MDM4-ALT2 in any of these normal tissues (Figure 1A).
However, one RMS tumor and its corresponding normal tissue,
N1007 and E1007, both expressed MDM4-ALT1 (Figure 1A).
Further, our analysis revealed coordination in MDM2-ALT1 and
MDM4-ALT2 with approximately 24% (16 of 66) of the patient
RMS samples analyzed showing the presence of both MDM2-ALT1
and MDM4-ALT2 transcripts. This co-occurrence of MDM2-ALT1
and MDM4-ALT2 was found to be statistically significant (Fisher
exact test, P = .0126).
Alternative Splicing of MDM2 and MDM4 Transcripts
Correlates with RMS Disease Stage
To assess the potential of these splicing events to serve as prognostic
markers for RMS disease states, we followed the disease progression
Figure 1. MDM2-ALT1 and MDM4-ALT2 are expressed in human RMS tumor samples. (A) Total RNA was isolated and assayed for
MDM2 and MDM4 splicing by RT-PCR in ARMS, ERMS, and anaplastic RMS samples as well as in matched normal muscle tissue
of five patients with RMS. Occurrence of splice variants MDM2-ALT1 and MDM4-ALT2 is strongly associated with ARMS and ERMS
subtypes but not with anaplastic RMS. (B) The statistical significance of the MDM2-ALT1 splicing between each group was determined
using the two-sided Fisher exact test. There was a significant difference in expression of MDM2-ALT1 between the alveolar or embry-
onal subtypes compared to the anaplastic RMS subtype (P < .0001). (C) All the RMS tumor samples were analyzed for correlation of the
presence of MDM4-ALT2 with subtypes of RMS as in B. There was a significant difference in expression of MDM4-ALT2 between the
alveolar (P = .0007) or embryonal (P = .0017) subtypes compared to the anaplastic RMS subtype.
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and survival of these patients in collaboration with the COG. Our
analytic population for this study included only 53 of the origi-
nal 70 patients whose tumors we assessed for MDM2 and MDM4
alternative splicing. This was due to unavailability of follow-up
data for 16 patients (9 of whom were non-COG patients). One pa-
tient who presented with RMS as a secondary malignancy was also
excluded from the analysis. We found no association between the
incidence of MDM2 and MDM4 alternative splicing with demo-
graphic characteristics such as age, sex, or ethnicity of the patients. In
addition, the EFS of the patients analyzed showed no correlation with
these demographic features. However, statistical analysis comparing
the progression of disease in these patients (analytic population with
a non-missing measure for at least one MDM splice variant and
available survival data) with the incidence of MDM2-ALT1 showed
that these transcripts are strongly associated with high-risk RMS (P =
.0288). Further, 91.6% (11 of 12) of the patients who presented with
Intergroup Rhabdomyosarcoma Study Group (IRSG) stage 4 (positive
for distant metastasis regardless of tumor size, site, invasiveness, and
lymph node involvement) metastatic disease were positive for MDM2-
ALT1 in their tumors (statistically significant, P = .0043; Table 1) com-
pared to only 47.2% (17 of 36 were MDM2-ALT1 positive) of the
patients who presented with IRSG stage 1, 2, and 3 disease. Similarly,
the presence ofMDM4-ALT2 in the tumors was associated significantly
(P = .0274) with invasive T2 stage (tumor extension and/or fixation to
surrounding tissue) RMS disease; 90.9% (10 of 11 tumors; Table 2) of
MDM4-ALT2–positive tumors were of T2 stage, while only 48.3% (14
of 29; Table 2) MDM4-ALT2–negative tumors were T2 stage. Overall,
we observed that 25 of 40 (62.5%) tumors that showed alternative
splicing of either MDM2 or MDM4 or both were of the invasive RMS
T2 type.
Notably, we found that the association of MDM2-ALT1 with
metastatic disease was not restricted to specific RMS subtypes. Of
the 11 (11 of 12; i.e., 91.6%) IRSG stage 4 metastatic tumors analyzed
that expressed MDM2-ALT1, 6 were alveolar (54.5%) and 5 were of
the embryonal (45.5%) subtype, indicating that MDM2-ALT1 is an
important biomarker of metastatic disease for both ARMS and ERMS
subtypes. Taken together, our study highlights that the alternative
splice variants MDM2-ALT1 and MDM4-ALT2 can potentially pre-
dict RMS disease severity, thereby serving as useful prognostic markers
for the most common RMS subtypes, ARMS and ERMS. However,
despite their strong correlation with high-risk RMS, these splice var-
iants do not seem to be predictors of patient survival within this dis-
ease category (Figure 2, A and B). In this study, the patients in the
high-risk category responded unusually well to treatment and showed
better EFS (log-rank P = .3763 for association of EFS with disease
risk level, data not shown) compared to historically recorded data for
this category.
MDM2-ALT1 and MDM4-ALT2 enhance anchorage-independent
growth of untransformedmyoblasts C2C12 andRh30RMS cells. As
MDM2-ALT1 and MDM4-ALT2 are strongly associated with alveolar
and embryonal tumors and also correlate with high-risk disease in
these categories, we wanted to test the possibility that these splice
variants can contribute to oncogenic transformation. Anchorage-
independent growth or the ability of cells to form foci when resus-
pended in solid media such as soft agar is an indicator of transformed
growth. Therefore, we assessed the anchorage-independent growth
of untransformed C2C12 myoblast cells that transiently expressed
LacZ, MDM2-ALT1, or MDM4-ALT2 for 0, 2, 4, or 7 days by mea-
suring the reduction of resazurin dye by the cells (a measure of the
metabolic activity of live and proliferating cells). Indeed, we observed
that the C2C12 myoblasts expressing MDM2-ALT1 and MDM4-
ALT2 showed significantly more growth (P < .05) at day 7 in soft
agar compared to the LacZ-expressing cells (Figure 3A).
Similarly, Rh30 RMS cells assayed for the effects of MDM2-
ALT1 and MDM4-ALT2 on their anchorage-independent growth
showed statistically significant (P < .05) increase in growth in solid
soft agar media between days 0 and 7, whereas the Rh30 cells express-
ing LacZ showed no significant changes in growth under the same
conditions (Figure 3B). Overexpression of the proteins from the trans-
fected constructs was verified in immunoblot analysis experiments
(Figure 3C ). Single bands were detected for overexpressed LacZ
(myc-tag antibody) at 120 kDa and for MDM4-ALT2 (MDM4
antibody) at approximately 40 kDa. Overexpressed MDM2-ALT1
was detected as a specific doublet by the MDM2 N20 antibody at
about 40 kDa, possibly due to the usage of an alternate translation
initiation codon downstream of the canonical start site in the MDM2-
ALT1 cDNA clone or posttranslational modifications of the over-
expressed protein. The transfected cells were also used for the migration
studies (below).
MDM2-ALT1 and MDM4-ALT2 expression leads to increased
invasive behavior of RMS cells. Due to the strong association of
MDM2-ALT1 and MDM4-ALT2 with metastatic RMS, we wanted
Table 1. MDM2-ALT1.
Characteristic MDM2-ALT1
Present, n (%)
MDM2-ALT1
Absent, n (%)
P Value (Fisher Exact Test)
IRSG stage
I 4 (14.3%) 6 (30%) .0043
II 6 (21.4%) 1 (5%)
III 7 (25%) 12 (60%)
IV 11 (39.3%) 1 (5%)
RMS risk level
Low 4 (13.8%) 5 (25%) .0288
Intermediate 14 (48.3%) 14 (70%)
High 11 (37.9%) 1 (5%)
n (Estimated
Survival %)
n (Estimated
Survival %)
P Value (Log-Rank Test)
Survival (5 years)
Low risk 4 (66.7%) 5 (100%) .2395
Intermediate risk 14 (71.4%) 14 (74.1%)
High risk 11 (67.5%) 1 (100%)
Table 2. MDM4-ALT2.
Characteristic MDM4-ALT2
Present, n (%)
MDM4-ALT2
Absent, n (%)
P Value (Fisher Exact Test)
RMS T stage
T1 1 (9.1%) 15 (51.7%) .0274
T2 10 (90.9%) 14 (48.3%)
n (Estimated
Survival %)
n (Estimated
Survival %)
P Value (Log-Rank Test)
Survival (5 years)
Low risk 3 (100%) 7 (85.7%) .873
Intermediate risk 6 (62.5%) 18 (77.4%)
High risk 4 (50%) 7 (75%)
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to test the possibility that expression of these splice forms could affect
the invasive behavior of RMS cell lines reflective of the metastatic po-
tential of these cells. To this end, we transiently transfected Rh30
cells (which do not constitutively express MDM2-ALT1 or MDM4-
ALT2) with plasmid constructs expressing myc-tagged MDM2-ALT1,
MDM4-ALT2, or LacZ (negative control) and assessed their inva-
sion through a matrigel-coated membrane in response to chemotactic
gradient (2% FBS to 15% FBS media). Our results showed that
MDM2-ALT1 and MDM4-ALT2 expression results in increased
invasiveness of Rh30 cells through the matrigel membrane (Figure 3D).
Quantification of the number of invaded cells followed by statistical
analysis revealed the increase in invasion by MDM2-ALT1–expressing
Rh30 cells to be statistically significant (P < .05) compared to the
LacZ-expressing Rh30 cells (Figure 3E).
Figure 2. MDM2-ALT1 and MDM4-ALT2 splicing do not correlate with patient survival. Five-year survival estimates of the patients in
each risk category were made using the Kaplan-Meier method. No significant correlation was observed when the proportional hazards
regression model was used for comparing the survival of patients (stratified according to RMS risk level) with occurrence of splice
variants (A) MDM2-ALT1 (stratified log-rank P = .2395) and (B) MDM4-ALT2 (stratified log-rank P = .8730).
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Effect of MDM2 and MDM4 alternative splicing on the p53
tumor suppressor pathway in tumor tissues. The expression of
MDM2 and MDM4 alternative transcripts has been shown to affect
the p53 pathway [1,12,13,25,31,32]. To examine the impact of
MDM2-ALT1 and MDM4-ALT2 expression on the p53 pathway in
RMS tumors, we assessed the levels of p53 and two of its downstream
targets by Western blot analysis in the four pairs of tumors for which
we were also able to obtain their corresponding matched normal tissues.
All four tumors examined expressed MDM2-ALT1, MDM4-ALT2,
or both (Figure 1A and Table W1). We found that p53 was over-
expressed in all four of the tumors compared to their paired normal
tissue (Figure 4). As p53 overexpression in tumors often results from
the presence of stabilizing but inactivating p53 gene mutations, we
sequenced the “hot spot” region of p53 cDNA from these patient
samples, exon 3 through exon 8, where the majority of known p53
mutations are found. All the samples examined were wild type for p53.
Additionally, we sequenced the p53 cDNA from 21 ARMS,
17 ERMS, and 19 anaplastic RMS tumors for which sufficient material
was available and discovered mutations in 3 of 21 ARMS tumors, 1 of
17 ERMS tumors, and 4 of 19 anaplastic RMS tumors. We did not
find any significant correlation between the presence of p53 mutations
and the presence of MDM2-ALT1 and/or MDM4-ALT2 transcripts.
Indeed, our data show that p53 mutations are prevalent in only 14%
Figure 3. MDM2-ALT1– and MDM4-ALT2–expressing cells show increase in migration and anchorage-independent growth. Rh30 RMS cells
and C2C12 myoblasts were transfected with LacZ, MDM2-ALT1, or MDM4-ALT2 expression constructs. The cells were used for soft agar
and/or matrigel invasion assays. (A) C2C12 cells expressing LacZ, MDM2-ALT1, or MDM4-ALT2 were seeded. Their growth was monitored
at days 0, 2, 4, and 7 after seeding. Data from three independent experiments with triplicate wells for each transfection group are repre-
sented graphically with SEM error bars. C2C12 cells expressing MDM2-ALT1 (P = .0117) and MDM4-ALT2 (P = .0054) show significantly
more anchorage-independent growth in soft agar at day 7 compared to LacZ-expressing cells. Additionally, comparison of growth in soft agar
between days 0 and 7 showed significant increases in the MDM2-ALT1 (P = .0025) and MDM4-ALT2 (P = .0296) groups but not in LacZ.
(B) Rh30 cells expressing LacZ, MDM2-ALT1, or MDM4-ALT2 were similarly assayed for anchorage-independent growth for 7 days in soft
agar. MDM2-ALT1 (P= .0109) andMDM4-ALT2 (P= .0389) expression caused significant increase in growth of Rh30 cells at day 7 compared
to day 0. LacZ-expressing Rh30 cells however showed no significant changes in growth in soft agar between days 0 and 7. (C) Western
blots confirming expression of LacZ, MDM2-ALT1, and MDM4-ALT2 in Rh30 and C2C12 cells at 24 hours post nucleofection. (D) Rh30 cells
expressing MDM2-ALT1 and MDM4-ALT2 show increased migration through matrigel-coated membranes (8-μm pore size) compared to Lac-
Z-expressing Rh30 cells. Representative ×10 magnification images of Rh30 cells post migration are shown here. (E) The matrigel invasion
experiments were performed in three independent trials, and the number of invasive cells was counted and represented graphically with
SEM error bars for each group. Unpaired Student’s t test comparing the mean number of cells in each group with LacZ-expressing cells
indicated a statistically significant increase (P = .0417, 95% CI) in invasive behavior of MDM2-ALT1–expressing Rh30 cells.
Figure 4. Human RMS tumors show alterations in p53 tumor
suppressor pathway. Tissue lysates of four RMS tumors and their
matched normal samples were examined for protein levels of p53
(DO-1; Santa Cruz Biotechnology) and its downstream transcrip-
tional targets p21 (F-5; Santa Cruz Biotechnology) and Bax (B-9;
Santa Cruz Biotechnology). β-Actin (AC-15; Sigma) was used as a
loading control. Of the four paired samples, p53 is overexpressed
in all tumor tissues when compared to corresponding normal tissue
(T, tumor tissues; N, normal muscle), although an up-regulation of
both p21 and Bax is seen in only one of the four tumors.
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of the RMS tumors tested. This is in accordance with other studies
in which low frequency of p53 mutations has been reported in RMS
tumors in general [33].
Despite the overexpression of p53 in the four tumor samples
(A0897, E1099, E1007, and A1008), it is possible that this crucial
tumor suppressor pathway has been inactivated downstream of p53
rendering it nonfunctional. Therefore, we tested the transcriptional
activity of p53 by examining the protein levels of p53 target genes
p21 (mediator of p53-dependent cell cycle G1 phase arrest) and Bax
(proapoptotic gene involved in induction of p53-mediated apoptosis)
in these tumors in comparison with the corresponding normal tissues
by Western blot analysis using β-actin as loading control. As predicted
by increased p53 protein levels, two of the tumors examined (A1008
and E1009) showed increased p21 levels compared to their match-
ing normal tissues (Figure 4). However, A0897 did not express p21,
suggestive of a lack of transcriptional activity of p53 in this tumor
(Figure 4). Bax was also upregulated in only two of the tumor samples
(Figure 4) when compared to the normal tissues (A0897 and A1008).
Although the number of tumors examined in this study is small
(the chief limitation being the lack of availability of matching nor-
mal muscle tissue), it is apparent that in the RMS tumors express-
ing MDM2 and MDM4 alternative transcripts, the p53 pathway has
been inactivated through different mechanisms. Accordingly, we
observed an inconsistency between p53 expression and activation of
one or more of its downstream target genes in three of the four tumor
samples (A0897, E1099, and E1007).
Stress Induction of Alternatively Spliced MDM2 and MDM4
Transcripts in RMS Cell Lines
MDM2-ALT1 and MDM4-ALT2 are generated on genotoxic
stress induction such as UV and cisplatin treatment in a variety of
cell lines in a p53-independent manner [11,12]. We sought to deter-
mine whether or not the stress-inducible alternative splicing pathway
was functional in RMS cell lines. When the RMS cell lines RD2,
Rh28, RH18, Rh3, CW9019, RH36, SMS-CTR, and Rh30 were
exposed to increasing doses of UV (0, 10, 30, and 50 J/m2) or
Figure 5. Alternatively spliced forms of MDM2 and MDM4 are induced by genotoxic stress in RMS cell lines. SMS-CTR and Rh30 RMS
cell lines were treated with increasing amounts of UV light (0, 10, 30, and 50 J/m2) or increasing concentrations of cisplatin (0, 25, and
50 μM) as represented by the corresponding increase in height of the triangle from left to right. Total RNA was harvested at 24 hours and
subjected to nested RT-PCR for MDM2 and MDM4. In response to increasing doses of UV and cisplatin, the SMS-CTR and Rh30 cell
lines show increased induction of (A) MDM2-ALT1 and (B) MDM4-ALT2. (C) For the ribosome profile analysis, RH3 cells were exposed
to 0 or 50 J/m2 UV and harvested 12 hours after treatment. Cytoplasmic extracts were separated on 15% to 50% linear sucrose density
gradients. RNA from each fraction was taken and subjected to nested RT-PCR for MDM2 and MDM4. Damage promoted enhanced
association of theMDM2-ALT1 andMDM4-ALT2 transcripts with polysomes in RH3 cells. Absorbance (A254) of RNA from each fraction
and the corresponding ribosome profile in normal (−UV) and treated (+UV) cells are represented in the graph.
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increasing doses of cisplatin (0, 25, and 50 μM in SMS-CTR and
Rh30) for 24 hours, we saw a time- and dose-dependent induction
of MDM2-ALT1 and MDM4-ALT2 in all of the cell lines tested
(Figure 5, A and B, and data not shown) irrespective of their p53
status. This confirms our previous finding that MDM2 alternative
splicing is p53 independent [11]. These results also indicate that
the pathways dictating stress-inducible MDM2 and MDM4 alterna-
tive splicing are intact and can be activated in all the RMS cell lines
tested. These findings raise the possibility that in the RMS tumors
in which these splice variants are constitutively expressed, similar
splicing regulatory pathways may be continuously activated even in
the absence of stress.
MDM2-ALT1 and MDM4-ALT2 transcripts show polysomal
loading. Although the alternative transcripts MDM2-ALT1 and
MDM4-ALT2 are readily detectable under stress and in certain
tumor types, it has proven to be a challenge to detect the proteins
generated from them in vivo. This is at least in part due to the un-
availability of efficient antibodies for MDM2-ALT1 and MDM4-
ALT2 recognition. In addition, most MDM2 and MDM4 antibodies
are targeted against internal epitopes, which are removed from the alter-
natively spliced isoform and therefore not usable to assess de novo
protein synthesis. We assessed the efficacy of a variety of MDM2
and MDM4 antibodies with C-terminal epitopes or whole recombi-
nant protein epitopes in detecting endogenous MDM2-ALT1 and
MDM4-ALT2 but failed to reliably detect these proteins in vivo. We
therefore resorted to an indirect method of assessing protein synthesis
from MDM2-ALT1 and MDM4-ALT2 transcripts and used sucrose
gradient analysis to determine the association of these transcripts with
polyribosomes [28]. We collected different mRNA fractions from
RH3 (RMS cell line) cells that were either untreated or treated with
UV (50 J/m2). We then queried for MDM2 and MDM4 isoforms
by RT-PCR analysis on these fractions. We observed the enhanced
presence of MDM2-ALT1 and MDM4-ALT2 in the polyribosome
fractions (15-21) of the sucrose gradients after exposure to UV
(Figure 5C ). The presence of the MDM2-ALT1 and MDM4-ALT2
transcripts in the polyribosome fraction is consistent with their acting
as substrates for cellular translational machinery in RH3 cells after UV
exposure (Figure 5C ).
Microarray detection of stress-responsive alternative splicing networks
in RMS cell lines. As RMS cell lines show coordinated splicing
of MDM2-ALT1 and MDM4-ALT2 on treatment with genotoxic
stress–inducing agents, we wanted to explore the possibility that
MDM2 and MDM4 form part of a stress-inducible alternative splicing
network that can affect the fate of the cell. To this end, we chose to
perform an exon microarray (Affymetrix Human Exon 1.0 ST array)
on Rh30 cells treated with 75 μM cisplatin and assessed changes in
the expression and splicing patterns of various genes in comparison
with untreated Rh30 cells (Figure 6A). Importantly, Rh30 cells express
MDM2-ALT1 and MDM4-ALT2 alternative splice variants only on
stress induction. All microarray targets showing alternative splicing
at P value < .05 with FDR correction were considered as being alter-
natively spliced under cisplatin and used for further analysis. Similarly,
only the microarray targets showing two-fold change in expression
levels and P < .05 with FDR correction were considered as showing
differential gene expression. Overall, we observed that 60.85% of the
genes showed no changes in expression or splicing on cisplatin treat-
ment (NC: 10,604 genes); 33.1% of the genes showed altered splicing
but no change in expression (AS: 5768); 4.57% of the genes showed
differential expression and altered splicing (AS + DE: 796), while
1.47% of the genes showed differential expression but not splicing
(DE: 256; Figure 6B). The top 700 genes in the AS, DE, and AS +
DE categories are listed in Table W3, A to C .
A subset of 14 alternatively spliced targets identified in the micro-
array (analyzed using the Partek Genomics software) as showing
marked changes in inclusion or exclusion of specific exons (Figure W1,
data not shown) was chosen for validation by PCR in the Rh30 cell
line. We confirmed that 12 (12 of 14, 85.7%) of these targets recapit-
ulated the results from the array and conformed to the microarray-
predicted changes in splicing of specific cassette exons (Figures 6C
and W2A), while 2 of these targets showed changes in transcript levels
but no alternative splicing (data not shown). Importantly,MDM2 was
also identified in our microarray as being differentially spliced on
cisplatin treatment (P = .00193). MDM4, although verified as show-
ing altered splicing patterns in cisplatin-treated Rh30 cells, could not
be detected in our exon microarray possibly due to limitations in the
available probe sets. We additionally validated splicing changes in
cisplatin-treated MCF7 cells and observed that 11 of 16 (69%) targets
tested were positive for alternative splicing changes as predicted
by the exon microarray (Figure W2A). In addition, we observed an
overlap in the stress-induced splicing of some of the targets identified
in our cisplatin treatment microarray with camptothecin drug–
induced alternative splicing (EED, PAPOLG, and THUMPD2; Fig-
ures 6C and W2A) [34]. We also chose a subset of eight differentially
expressed genes for validation in Rh30 cells by semiquantitative
PCR. Of the eight targets tested, seven genes recapitulated the expres-
sion changes predicted by the microarray under cisplatin treatment
(Figure W2B).
We then used the DAVID online bioinformatics tool (gene ontology
analysis) to determine if the stress-inducible alternative splicing events
identified in our exon microarray are part of splicing networks affected
in various cellular processes or signaling pathways (alternative splicing
P values < .05 with FDR correction in cisplatin vs control). Interestingly,
Kyoto Encyclopedia of Genes and Genomes (KEGG) [35,36] pathways
associated with the alternatively spliced genes showed the highest en-
richment in cancer and related pathways including the cell cycle and
p53 signaling pathway (Figure W3). These pathways are mapped out
as shown in Figure W4 with the labeling indicating the genes in these
pathways that show significantly altered splicing under cisplatin treat-
ment (Figure W4, A and B). The high correlation between genotoxic
stress–induced (cisplatin treatment) alternative splicing changes and
genes involved in cancer is suggestive of the presence of cognate splicing
networks in cancer and stress response.
RMS tumors share features of stress-responsive alternative splicing
networks. To test the possibility that RMS tumors show splicing
patterns similar to stress response aside from MDM2 and MDM4
alternative splicing, we assessed the pre-mRNA splicing of five tar-
get genes (identified from exon microarray) in two alveolar (A4217
and A1063) and one embryonal tumor (E2035) from our original
panel in comparison with normal human muscle tissue mRNA (Life
Technologies and Clontech; Figure 6C). All of these tumors showed
the presence of MDM2-ALT1 and MDM4-ALT2. Indeed, the splic-
ing of four of these genes (CEP97, PELI1, EED, and LSM1) in our
tumor samples was similar to their splicing patterns observed (in exon
microarray and splicing validation experiments) in cisplatin-treated
Rh30 cells (Figure 6, C andD). One of the targets (C13orf23) however
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showed no change in splicing between normal muscle and tumor
tissue (Figure 6C) as predicted by the microarray (P = .453), although
the Rh30 and MCF7 cell lines showed cisplatin and UV-induced alter-
native splicing of this pre-mRNA (Figures 6C and W2). This provides
evidence that at least a part of the splicing landscape in RMS tumors
has shared components with stress response splicing pathways.
Discussion
MDM2-ALT1 and MDM4-ALT2 Linked to
Advanced-Stage Disease
Our study has demonstrated strong subtype specificity for
the occurrence of stress-inducible splice variants MDM2-ALT1 and
MDM4-ALT2 with the ARMS and ERMS subtypes but not with
anaplastic RMS. Statistical analysis of patient survival and disease
outcome in relation to these alternative splice forms showed the
highly significant correlation between the presence of MDM2-ALT1
and MDM4-ALT2 transcripts and advanced-stage RMS disease.
Indeed, 11 of 12 (91.6%) patients with advanced metastatic IRSG
stage 4 disease expressed MDM2-ALT1 predicting an overall poor
outcome for these patients solely due to the advanced stage of the
disease. However, stratification of patient outcome according to dis-
ease risk level showed no significant association of MDM2-ALT1 with
EFS within the high-risk group. This is because high-risk patients in
this study had an increased survival rate when compared to historical
data (61.4% in this study versus the historically recorded 25% EFS
Figure 6. Stress-induced alternative splicing networks share common features with RMS tumors. Human Exon 1.0 ST Array was used to
examine alternative splicing events induced on cisplatin treatment of Rh30 cells (75 μM for 12 hours). (A) Heat map displaying differential
expression of genes between normal and cisplatin-treated Rh30 cells for three biologic replicates. (B) Pie chart displaying the number of
genes showing alternative splicing and/or differential expression and those that remain unchanged on cisplatin treatment. The DE grouping
contains genes with two-fold changes in expression levels and P < .05 with FDR correction. The AS group contains all genes that show
alternative splicing at P value < .05 with FDR correction. (C) Pre-mRNA from three RMS tumors (alveolar A4217 and A1063 and embryonal
E2035) that showed the presence of bothMDM2-ALT1 andMDM4-ALT2 and normal skeletal muscle tissue (Clontech and Life Technologies)
was assayed for the splicing of five targets identified in the exon microarray. All the RMS tumors examined in comparison with normal
skeletal muscle tissue showed splicing patterns similar to cisplatin-treated Rh30 cells. (D) Table showing the documented functions
of CEP97, PELI1, EED, LSM1, and C13orf23, which were examined for altered splicing in the RMS tumors. The P values indicated in the
table represent the significance of the difference in the expression of the cassette exon (Figures 5C andW1) in these genes between normal
and stress conditions as determined using the Partek software.
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estimate for this group). This could be due to changes in treatment
regimens over the years that could have altered the response of this
group of patients to chemotherapy. In addition, it is possible that the
small sample numbers of high-risk disease patients (n = 12) involved in
this study could have led to an overrepresentation of the patients with
a better treatment response. Moreover, it should be noted that only 1 of
the 12 high-risk patients lacked expression of MDM2-ALT1, and this
low number of samples may be insufficient for adequate statistical
analyses. However, it may be possible that MDM2-ALT1 occurrence
in high-risk RMS disease could be associated with better patient prog-
nosis within this risk category. Unfortunately, MDM2-ALT1 status is
not available for the historical data that predict only 25% 5-year EFS
for the high-risk group. Therefore, a study on a much larger scale with
high-risk RMS patients would be required to test this possibility.
Strikingly, the 11 IRSG stage 4 tumors that were MDM2-ALT1
positive comprised almost equal numbers of alveolar (6 of 11; i.e.,
54.5%) and embryonal (5 of 11; i.e., 45.5%) subtypes. This is an
important observation as it points toward MDM2-ALT1 as a novel
predictor of metastatic disease transcending the two main RMS sub-
types. To date, prognosis assessment for RMS has chiefly relied on
subtype histology (alveolar or embryonal), number of metastases,
regional lymph node involvement, and molecular markers such as
PAX/FOXO1 translocation status of the tumor. However, the molec-
ular factors are geared more toward predicting disease outcome for
the alveolar subtype and there is no reliable marker available for
metastatic disease of both the embryonal and alveolar subtypes. Our
observations show that MDM2-ALT1 can potentially serve as a prog-
nostic marker for metastatic disease irrespective of tumor histology. In
conclusion, our study and those of others have irrefutably shown that
altered MDM2 and MDM4 splicing is a persistent feature of RMS
tumors and our study is the first to show a strong subtype-independent
association of stress response splice variantsMDM2-ALT1 andMDM4-
ALT2 with advanced-stage RMS disease.
p53 Pathway and MDM2 and MDM4 Splicing
We observed a very low frequency of p53 mutations (14%) in
the RMS tumors that we tested, thereby corroborating previous
studies in which mutant p53 was a rare feature in pediatric RMS
[33]. Given that p53 is perhaps the most commonly mutated gene
in human cancers, and that p53 mutations are absent in a larger per-
centage of RMSs, it is an intriguing possibility that altered splicing
of MDM2 and MDM4 is an important step that leads to oncogenic
transformation. However, it is also possible that in a majority of these
tumors the p53 tumor suppressor pathway is disabled through an
alternative mechanism or that other oncogenic programs are at play.
Indeed, our results, despite the small sample number, are suggestive
of a non-functional p53 tumor suppressor pathway or an uncoupling
of the normal pathway in these tumors. This may be attributed either
to misregulations in the p53 pathway or to additional, potentially
p53-independent functions of the alternatively spliced forms of
MDM2, MDM4, or both. This is consistent with previous studies on
STS tumors in which a statistically significant association was observed
between MDM2 alternative splice variant expression and elevated
p53 protein levels [1].
MDM2-ALT1 and MDM4-ALT2 as Potential
Transforming Factors
We have shown here that MDM2-ALT1 and MDM4-ALT2 when
expressed in Rh30 cells, which are heterozygous for the R273C p53
missense mutation (inactive p53) [37,38], can directly affect their
migration through a matrigel membrane (reflective of metastatic be-
havior) and also their anchorage-independent growth in soft agar.
Importantly, MDM2-ALT1 and MDM4-ALT2 cause an increase in
the anchorage-independent growth of untransformed C2C12 cells,
suggesting that they possibly play a role in transformation of cells in
the context of RMS. However, the mechanism by which they function
in oncogenesis is not yet known. The inhibition of p53 by full-length
MDM2 relies on the p53-binding domain [39,40], which is excluded
in MDM2-ALT1. Therefore, it is unlikely that MDM2-ALT1 can
directly affect p53 activity. However, MDM2-ALT1 has been shown
to interact with and sequester full-length MDM2 in the cytoplasm
[11,12], thereby potentially stabilizing p53. This could be a possible
mechanism by which p53 levels are elevated in RMS tumors express-
ing MDM2-ALT1. Alternatively, MDM2 has documented p53-
independent roles, which become apparent in the absence of p53
[41–45]. The exogenous expression of MDM2-ALT1 has been
shown to have oncogenic functions in p53-null mouse embryonic
fibroblasts and NIH3T3 cells. Further, the expression of Mdm2-b
(mouse homolog of MDM2-ALT1) under a glial fibrillary acidic
protein promoter spontaneously induced the formation of myeloid
sarcomas and B cell lymphomas in transgenic mice [46]. It is there-
fore likely that MDM2-ALT1 could retain or even affect the p53-
independent properties of full-length MDM2, thereby influencing
tumor formation in a p53-independent context as well. Furthermore,
it has been shown that MDM2 gene dosage can affect the rate of
tumorigenesis and also tumor spectrum in mice with compromised
Arf and/or p53 [43,45,47]. Therefore, the presence of MDM2 splice
variants that are capable of interacting with and sequestering full-
length MDM2 can be viewed as a means of altering the MDM2 gene
dosage, which can eventually affect tumorigenesis and/or metastasis.
Additionally, the presence of MDM4 alternative transcripts could
influence tumorigenesis by affecting MDM4 gene dosage in a scenario
similar to MDM2. For instance, MDM4-S, a splice variant of MDM4
that lacks exon 6, is associated with poor prognosis especially in some
types of sarcomas. This is mainly due to the fact that high MDM4-S
levels result in low levels of full-length MDM4, and consequently,
this selective pressure leads to MDM2 overexpression and/or p53
mutations [15,24]. It is therefore possible that MDM4-ALT2, which
is architecturally similar to MDM2-ALT1, could have functions that
manipulate the p53 pathway leading to cancer. Furthermore, distinct
functions have been described for MDM2 and MDM4 in the con-
trol of p53 activity [48], although the collaboration of MDM2 and
MDM4 is important for the regulation of p53 [49,50]. Therefore,
we speculate that the coordinated splicing of MDM4-ALT2 with
MDM2-ALT1 could also affect tumorigenesis in these RMS samples
in ways unique to each. It is also possible that other tumor sup-
pressor or oncogenic pathways besides the p53-MDM2 axis have
been affected by global changes in the splicing pathways in the RMS
tumors that impact tumorigenesis.
Genotoxic Stress Response and Cancer: Similarities in
Splicing Networks
Our data mining experiments using DAVID Bioinformatics Re-
sources for gene ontology analysis implicated cancer-related pathways
as being highly enriched for alternative splicing under DNA damage
or genotoxic stress. Similar observations were made by Muñoz et al. in
that genes involved in cell cycle, cancer, and cell death were highly
enriched for alternative splicing events on UV irradiation (genotoxic
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stress) [51]. Taken together, these observations suggest that gene
expression regulation through alternative splicing is an important
component of cellular stress response (including cell cycle checkpoint,
DNA damage repair, and apoptotic and other tumor-suppressive
pathways frequently misregulated in cancer). Strikingly, when three
RMS tumors from our original panel, which were constitutively pos-
itive for both MDM2-ALT1 and MDM4-ALT2 splicing, were tested
for other stress-responsive splicing patterns (based on exon microarray
prediction), we found that in four of five genes assayed, the RMS
tumors showed similarities to cisplatin-treated Rh30 cells. This sug-
gests that at least a part of the splicing networks that are constitutively
altered in these tumors bear features reminiscent of stress-responsive
alternative splicing changes.
These data raise the possibility that activation of stress response
measures including alternative splicing pathways due to prolonged
exposure to stress stimuli can pave the way for tumorigenesis. It
has been implied in various studies that persistent DNA damage
signals can induce some cells to respond by evading apoptosis and
entering a phase of senescence [52–57], thereby setting the stage for
carcinogenesis. It is possible that the RMS tumors examined here arose
under similar circumstances in that persistent genotoxic stress response
events could have contributed to splicing alterations, which in turn
could have led to tumorigenesis. Consideration of such a scenario leads
to speculation about the advisability of further using DNA damage
agents as chemotherapeutic drugs for tumors where stress-induced
alterations are already in place. Just as there are two sides to a coin,
it is possible that the use of DNA damage agents such as cisplatin
in chemotherapy could, on the one hand, harness the corresponding
repair pathways and activate apoptosis and, on the other hand, could
actually prove to be detrimental in these tumors by eliciting additional
persistent stress response signals and possibly drug resistance. There-
fore, in-depth probing of the splicing networks in the different sub-
types of RMS and also other tumor types that show constitutive
stress response–like splicing is necessary before considering therapeutic
modalities that target these pathways.
Moreover, many cancer therapies rely on the reactivation of the
p53 pathway in tumors, and newer strategies that involve targeting
the p53-negative regulators, MDM2 and MDM4, are also being
explored for development of cancer therapies [58,59] including small
molecule MDM inhibitors such as nutlin3a. The effectiveness of
such inhibitors of MDM2 and p53 interaction on RMS has been
assessed on xenograft tumors and cell line models of RMS and at
least one small molecule inhibitor has been reported to be able to
reactivate both mutant and wild-type p53 pathways [60–62]. How-
ever, the presence of alternative splice variants of MDM2 and MDM4
should be taken into account as these isoforms may potentially change
the outcome of the treatment. Further, these therapies may fail in these
cancer types where the p53 pathway, although activated, is possibly
rendered nonfunctional by the alternative splice forms MDM2-ALT1
and MDM4-ALT2 through the uncoupling of p53 from the regulation
of cell cycle and/or apoptosis. Therefore, the precise signaling pathways
and mechanisms involved in the initiation of alternative splicing
of MDM2 and MDM4 need to be understood as they may provide
clues necessary for the development of novel therapeutic agents for
the treatment of these otherwise resistant tumors. One mechanism
by which alternative pre-mRNA splicing can be effected is differential
promoter usage for gene transcription [63].MDM2 transcripts originate
from two promoters P1 (p53-independent) and P2 (p53-dependent)
with different 5′ untranslated regions (5′UTRs) albeit translating into
identical protein products [64]. Our assay for MDM2 alternative splice
forms could not assess promoter usage. However, previous reports of
MDM2 alternative splicing in tumors have shown that there is no sig-
nificant association between the alternative transcripts and MDM2
promoter usage [4,6]. To dissect other possible mechanisms that
mediate this splicing event, we have developed an in vitro minigene-
based system that effectively simulates the stress-induced generation of
MDM2-ALT1 transcripts [65].
The impact of splicing regulatory pathways on p53 response has
been highlighted in a recent study that showed that p53 is upregulated
when core spliceosomal machinery components are knocked down
[66]. The importance of altered splicing events in tumor-suppressive
and oncogenic pathways opens a new avenue for therapeutic inter-
vention in tumors where aberrant splicing events have been observed.
Our data show that alternative splicing of MDM2 and MDM4 is an
important feature of high-grade disease for specific types of RMS
tumors. Additionally, we have identified a parallel between stress-
inducible alternative splicing and the constitutively active alternative
splicing pathways in these RMS tumors. We made an inquiry into
the splicing networks altered in the RMS cell line Rh30 in response
to genotoxic stress (cisplatin) in an attempt to understand the nature
of stress-induced splicing pathways in RMS. In addition, we have
observed that these networks overlap with those that show alterations
in splicing patterns in RMS tumors. This knowledge will help to isolate
specific factors that can be targeted for splicing correction therapies
for RMS.
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Figure W1. Partek representation of cisplatin-induced alternative splicing events. Splicing of the exons of selected genes (subsequently
validated by PCR; Figure 6C ) under normal and cisplatin-treated conditions is represented using plots generated by Partek genomics
software on analysis of the exon microarray data. Each point represents the average expression level of the corresponding exon in each
treatment group (three cisplatin vs three control samples). Representative transcripts for each gene are shown above the plots. Red
represents cisplatin treatment, and blue represents normal conditions. The arrows indicate the alternatively spliced cassette exon.
Figure W2. Validation of exon microarray targets in Rh30 and MCF7 cell lines. Rh30 and MCF7 cells were treated with 75 μM cisplatin or
50 J/m2 UV as indicated for 24 hours, and total RNA was harvested. (A) Fifteen targets from the exon microarray that were predicted
to show significantly altered splicing of cassette exons under stress were tested in these cell lines. Of the 15 targets, 12 were validated
in Rh30 cells and 11 in MCF7 cells, and they recapitulated the splicing changes predicted by the exon array. The 11 targets validated in
MCF7 cells and 7 of the 12 targets in Rh30 cells (the validation of the other 5 targets is shown in Figure 6) are shown here. (B) Eight
targets that were predicted in the exon microarray to show significantly altered gene expression (increase or decrease) under cisplatin
treatment were validated in Rh30 cells for differential expression between normal and cisplatin-treated conditions. Seven of the eight
targets recapitulated the predicted expression changes (TMEM133 being the exception).
Figure W3. Pathway enrichment analysis of genotoxic stress–induced alternatively spliced genes reveals enrichment of genes involved
cancer and related pathways. Alternatively spliced genes (alternative splicing P < .05 including FDR) were analyzed for ontology using
DAVID bioinformatics tools. Y values indicate −log10 of the enrichment P values, denoting the magnitude of correlation between the
alternatively spliced gene sets and establishedmolecular pathways. While the genes showing alterations in splicing patterns under cisplatin
treatment fell into a number of categories of biologic processes, we have represented here the most relevant and highly enriched pathways
relating to cancer and associated cellular processes.
Figure W4. Enriched KEGG functional pathways of alternatively spliced genes under cisplatin treatment. KEGG functional pathway [31,32]
analysis (part of the DAVID bioinformatics tools) was performed on the genes undergoing alternative splicing on cisplatin treatment (genes
significantly differentially spliced are denoted by red circles): (A) p53 tumor suppressor pathway and (B) cell cycle control, two categories
for which the stress-responsive alternative splicing events were highly enriched and which are relevant in the context of cancer.
